Literature DB >> 23659303

Viral vaccines for bony fish: past, present and future.

Celene Salgado-Miranda1, Elizabeth Loza-Rubio, Edith Rojas-Anaya, Gary García-Espinosa.   

Abstract

Since 1970, aquaculture production has grown. In 2010, it had an annual average rate of 6.3% with 59.9 million tons of product and soon could exceed capture fisheries as a source of fishery products. However, the occurrence of viral diseases continues to be a significant limiting factor and its control is important for the development of this sector. In aquaculture farms, fish are reared under intensive culture conditions, and the use of viral vaccines has enabled an increase in production. Several types of vaccines and strategies of vaccination have been developed; however, this approach has not reached the expected goals in the most susceptible stage (fingerlings). Currently, there are inactivated and recombinant commercial vaccines, mainly for salmonids and cyprinids. In addition, updated genomic and proteomic technology has expedited the research and expansion of new vaccine models, such as those comprised of subunits or DNA. The objective of this review is to cover the various types of viral vaccines that have been developed and are available for bony fishes, as well as the advantages and challenges that DNA vaccines present for massive administration in a growing aquaculture, possible risks for the environment, the controversy regarding genetically modified organisms and possible acceptance by consumers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23659303     DOI: 10.1586/erv.13.38

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

1.  Rational development of an attenuated recombinant cyprinid herpesvirus 3 vaccine using prokaryotic mutagenesis and in vivo bioluminescent imaging.

Authors:  Maxime Boutier; Maygane Ronsmans; Ping Ouyang; Guillaume Fournier; Anca Reschner; Krzysztof Rakus; Gavin S Wilkie; Frédéric Farnir; Calixte Bayrou; François Lieffrig; Hong Li; Daniel Desmecht; Andrew J Davison; Alain Vanderplasschen
Journal:  PLoS Pathog       Date:  2015-02-20       Impact factor: 6.823

2.  P247 and p523: two in vivo-expressed megalocytivirus proteins that induce protective immunity and are essential to viral infection.

Authors:  Jian Zhang; Bao Cun Zhang; Li Sun
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

3.  Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.

Authors:  Qi-Jie Zhang; Jiao-Chen Luan; Le-Bin Song; Rong Cong; Cheng-Jian Ji; Xiang Zhou; Jia-Dong Xia; Ning-Hong Song
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

4.  pH-Controlled Release of Antigens Using Mesoporous Silica Nanoparticles Delivery System for Developing a Fish Oral Vaccine.

Authors:  Weibin Zhang; Chunhua Zhu; Fangnan Xiao; Xiaodong Liu; Anhua Xie; Fangman Chen; Panpan Dong; Pingdong Lin; Chenyang Zheng; Hong Zhang; Hui Gong; Yunkun Wu
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

5.  Update on the Inactivation Procedures for the Vaccine Development Prospects of a New Highly Virulent RGNNV Isolate.

Authors:  Alberto Falco; Melissa Bello-Perez; Rocío Díaz-Puertas; Matthew Mold; Mikolaj Adamek
Journal:  Vaccines (Basel)       Date:  2021-12-07

Review 6.  Challenges and Solutions to Viral Diseases of Finfish in Marine Aquaculture.

Authors:  Kizito K Mugimba; Denis K Byarugaba; Stephen Mutoloki; Øystein Evensen; Hetron M Munang'andu
Journal:  Pathogens       Date:  2021-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.